Citadel Advisors
RNAC icon

Citadel Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Citadel Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$677K Buy
110,128
+30,343
+38% +$216K ﹤0.01% 8565
2025
Q4 		$575K Buy
79,785
+9,261
+13% +$74.9K ﹤0.01% 8689
2025
Q3 		$721K Sell
70,524
-50,350
-42% -$566K ﹤0.01% 8277
2025
Q2 		$1.26M Sell
120,874
-26,423
-18% -$281K ﹤0.01% 6601
2025
Q1 		$1.94M Sell
147,297
-167,703
-53% -$3M ﹤0.01% 5589
2024
Q4 		$5.64M Sell
315,000
-60,767
-16% -$1.23M ﹤0.01% 3763
2024
Q3 		$5.76M Buy
+375,767
New +$5.87M ﹤0.01% 3728
2024
Q2 		– Sell
-3,318
Closed -$64.7K – 15214
2024
Q1 		$64.7K Sell
3,318
-14,252
-81% -$302K ﹤0.01% 11916
2023
Q4 		$363K Sell
17,570
-1,585
-8% -$47.3K ﹤0.01% 8760
2023
Q3 		$609K Buy
19,155
+644
+3% +$21.5K ﹤0.01% 7626
2023
Q2 		$622K Buy
18,511
+1,588
+9% +$56.8K ﹤0.01% 7451
2023
Q1 		$706K Buy
16,923
+10,840
+178% +$510K ﹤0.01% 7547
2022
Q4 		$206K Sell
6,083
-22,184
-78% -$944K ﹤0.01% 10081
2022
Q3 		$1.39M Buy
28,267
+19,196
+212% +$1.05M ﹤0.01% 6309
2022
Q2 		$357K Sell
9,071
-1,140
-11% -$33.8K ﹤0.01% 9418
2022
Q1 		$377K Buy
10,211
+2,381
+30% +$149K ﹤0.01% 10062
2021
Q4 		$765K Buy
7,830
+4,368
+126% +$470K ﹤0.01% 8597
2021
Q3 		$432K Sell
3,462
-548
-14% -$66.2K ﹤0.01% 10239
2021
Q2 		$503K Sell
4,010
-2,832
-41% -$337K ﹤0.01% 10050
2021
Q1 		$929K Buy
6,842
+2,996
+78% +$372K ﹤0.01% 8305
2020
Q4 		$350K Buy
3,846
+3,277
+576% +$284K ﹤0.01% 8794
2020
Q3 		$42K Buy
+569
New +$43.6K ﹤0.01% 9661
2020
Q2 		– Sell
-56,511
Closed -$4.09M – 10397
2020
Q1 		$4.09M Buy
+56,511
New +$5.46M ﹤0.01% 2988
2019
Q1 		– Sell
-739
Closed -$59K – 9774
2018
Q4 		$59K Buy
+739
New +$169K ﹤0.01% 8447

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's RNAC Position: Q1 2026 in Review

Citadel Advisors increased its Cartesian Therapeutics (RNAC) stake by 38% in Q1 2026, buying an estimated $216K and bringing the position to 110,128 shares worth $677K. The position accounts for ﹤0.01% of the portfolio, ranked #8565.

Citadel Advisors first reported a position in RNAC in Q4 2018 and has held it in 24 quarters since. The position peaked at $5.76M in Q3 2024. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Citadel Advisors held 110,128 shares of Cartesian Therapeutics worth $677K as of Q1 2026.
  • Citadel Advisors bought 30,343 Cartesian Therapeutics shares in Q1 2026, an estimated $216K.
  • Cartesian Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8565 holding.
  • Citadel Advisors first reported a position in Cartesian Therapeutics in Q4 2018 and has held it in 24 quarters since.
  • Citadel Advisors's Cartesian Therapeutics position peaked at $5.76M in Q3 2024.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.